Anzorpharma
Anzor Pharmaceuticals develops peptide and small‑molecule therapeutics that modulate fibroblast growth factor receptors (FGFRs) for metabolic disease, wound healing, and tissue regeneration. Their platform includes both FGFR agonists and antagonists to address diverse clinical targets. The company recently secured a patent for a novel α‑Klotho protein therapy, expanding its pipeline in protein‑based drug development.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Anzor Pharmaceuticals develops peptide and small‑molecule therapeutics that modulate fibroblast growth factor receptors (FGFRs) for metabolic disease, wound healing, and tissue regeneration. Their platform includes both FGFR agonists and antagonists to address diverse clinical targets. The company recently secured a patent for a novel α‑Klotho protein therapy, expanding its pipeline in protein‑based drug development.